Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Image 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Table 5_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

“…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”

Prevalence of Vision Loss in North Africa and Middle East in 2020: Magnitude and Temporal Trends by Vision Loss Expert Group of the Global Burden of Disease Study (20987841)

“…</p> <p>Although the absolute numbers of people with blindness and MSVI have increased between 1990 and 2020 in NAME region, the overall prevalence and the age standardized prevalence in those aged 50+ years have decreased significantly for the same period.</p>…”

Image 3_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Table 1_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Image 2_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Table 2_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Image 1_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Image 4_Impact of social factors and health campaigns on the burden of idiopathic epilepsy: an inequality, decomposition, generalized and synthetic difference-in-differences study.... by Xuewen Rong (6242657)

“…The slope index of inequality for the mortality burden decreased from 1.97 to 1.62. After the policy shock, the age-standardized rate (ASR) of years lived with disability (YLD) in the Caribbean increased significantly to 4.59 (95% CI: 0.96 to 8.22), while the all-age YLD rate in the U.S. increased (5.18, 95% CI: 0.66 to 9.70) for both sexes.…”

Data corresponding to the publication by Di Miceli, Rossitto, Martinat, Marchaland, Kharbouche, Graland, Younes, Séré, Aubert, Rabbaa Khabbaz, Madore, Delpech, Martín & Layé. by Mathieu Di Miceli (6318911)

“…At both PND21 and PND55, animals from both sexes born by C-section presented significantly decreased time spent in the open arm of the Elevated Plus Maze test, compared to control animals. …”

Table 1_Global burden of lower respiratory infections attributable to cytomegalovirus, 1990–2021: a systematic analysis from the MICROBE database.docx by Wanwan Zhang (1550911)

“…Objectives<p>This study aimed to investigate the global epidemiological characteristics and disease burden of lower respiratory infections (LRIs) attributable to cytomegalovirus (CMV) from 1990 to 2021.</p>Methods<p>We systematically assessed the global burden and temporal trends of CMV-associated LRIs across different ages, sexes, geographic regions, and socioeconomic statuses using data from the MICROBE database spanning 1990–2021. …”